These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 11142476

  • 1. A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study.
    Miller WH, Reyno LM, Loewen GR, Huan S, Winquist E, Moore M, Cato A, Jaunakais D, Truglia JA, Matthews S, Dancey J, Eisenhauer E.
    Ann Oncol; 2000 Nov; 11(11):1387-9. PubMed ID: 11142476
    [Abstract] [Full Text] [Related]

  • 2. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
    Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM.
    J Immunother; 2007 Sep; 30(6):655-62. PubMed ID: 17667529
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.
    Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM.
    Cancer; 2002 Sep 15; 95(6):1220-7. PubMed ID: 12216088
    [Abstract] [Full Text] [Related]

  • 4. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
    Olencki T, Peereboom D, Wood L, Budd GT, Novick A, Finke J, McLain D, Elson P, Bukowski RM.
    J Cancer Res Clin Oncol; 2001 May 15; 127(5):319-24. PubMed ID: 11355147
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
    Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L.
    J Clin Oncol; 2001 Mar 01; 19(5):1312-9. PubMed ID: 11230473
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer.
    Rizvi NA, Marshall JL, Ness E, Yoe J, Gill GM, Truglia JA, Loewen GR, Jaunakais D, Ulm EH, Hawkins MJ.
    Clin Cancer Res; 1998 Jun 01; 4(6):1437-42. PubMed ID: 9626460
    [Abstract] [Full Text] [Related]

  • 7. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
    Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM.
    J Clin Oncol; 1995 Aug 01; 13(8):1950-7. PubMed ID: 7636535
    [Abstract] [Full Text] [Related]

  • 8. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
    Toma S, Raffo P, Nicolo G, Canavese G, Margallo E, Vecchio C, Dastoli G, Iacona I, Regazzi-Bonora M.
    Int J Oncol; 2000 Nov 01; 17(5):991-1000. PubMed ID: 11029503
    [Abstract] [Full Text] [Related]

  • 9. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M.
    Clin Cancer Res; 2000 Sep 01; 6(9):3442-50. PubMed ID: 10999727
    [Abstract] [Full Text] [Related]

  • 10. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS.
    Cancer; 1993 Sep 01; 72(5):1733-42. PubMed ID: 8348502
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.
    Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, Negrier S, Ernst S, Siebels M, Ginsberg M, Rittweger K, Hooftman L.
    Ann Oncol; 2002 Nov 01; 13(11):1799-805. PubMed ID: 12419754
    [Abstract] [Full Text] [Related]

  • 12. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
    Mittelman A, Huberman M, Puccio C, Fallon B, Tessitore J, Savona S, Eyre R, Gafney E, Wick M, Skelos A.
    Cancer; 1990 Aug 15; 66(4):664-9. PubMed ID: 2386896
    [Abstract] [Full Text] [Related]

  • 13. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM.
    J Clin Oncol; 2004 Jul 15; 22(14):2891-900. PubMed ID: 15254058
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G, Dillman RO, Wiemann MC, Stark JJ, Tai F, DePriest CB, Church CK, Schulof R.
    Cancer Biother Radiopharm; 2002 Apr 15; 17(2):165-73. PubMed ID: 12030110
    [Abstract] [Full Text] [Related]

  • 15. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
    Kankuri M, Pelliniemi TT, Pyrhönen S, Nikkanen V, Helenius H, Salminen E.
    Cancer; 2001 Aug 15; 92(4):761-7. PubMed ID: 11550145
    [Abstract] [Full Text] [Related]

  • 16. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.
    Hofmann WK, Kell WJ, Fenaux P, Castaigne S, Ganser A, Chomienne C, Burnett R, Kowal C, Hoelzer D, Burnett AK.
    Leukemia; 2000 Sep 15; 14(9):1583-8. PubMed ID: 10995004
    [Abstract] [Full Text] [Related]

  • 17. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
    Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL.
    J Clin Oncol; 2002 Sep 15; 20(18):3841-9. PubMed ID: 12228203
    [Abstract] [Full Text] [Related]

  • 18. Interferon alfa-2a tretinoin in patients with metastatic renal cell carcinoma: a pilot study.
    Paule B, Bonhomme-Faivre L, Rudant E, Ferrière F.
    Am J Health Syst Pharm; 1997 Jan 15; 54(2):190-2. PubMed ID: 9117809
    [No Abstract] [Full Text] [Related]

  • 19. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL.
    J Clin Oncol; 1996 Aug 15; 14(8):2234-41. PubMed ID: 8708712
    [Abstract] [Full Text] [Related]

  • 20. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
    Clark JI, Kuzel TM, Lestingi TM, Fisher SG, Sorokin P, Martone B, Viola M, Sosman JA.
    Ann Oncol; 2002 Apr 15; 13(4):606-13. PubMed ID: 12056712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.